Related Experiment Video
Updated: Jun 4, 2026
06:19
Intracameral Injection in Rats with Low Risk of Adverse Effects
Published on: May 31, 2024
Emerging drugs for ocular hypertension.
1Eye Associates, Floor 4, 187 Macquarie Street, Sydney, NSW 2000, Australia.
Expert Opinion on Emerging Drugs
|March 1, 2011
Summary
Glaucoma and ocular hypertension treatments are reviewed, including current medications and novel agents targeting aqueous humor dynamics. Future therapies aim for better intraocular pressure control and improved drug delivery to combat vision loss.
Area of Science:
- Ophthalmology
- Pharmacology
Background:
- Glaucoma is a leading cause of irreversible blindness, characterized by optic disc and visual field changes.
- Ocular hypertension (OH) is a major risk factor for glaucoma, involving elevated intraocular pressure without optic nerve damage.
Purpose of the Study:
- To review current ocular hypotensive medications for glaucoma and OH.
- To explore novel therapeutic agents and drug delivery systems for enhanced glaucoma management.
Main Methods:
- Review of existing glaucoma pharmacotherapies: prostaglandin analogs, beta-blockers, alpha-agonists, carbonic anhydrase inhibitors, and parasympathomimetics.
- Exploration of emerging drug classes targeting trabecular meshwork outflow, such as Rho-kinase inhibitors and ion-channel modulators.
- Discussion of potential future agents including serotonergics, cannabinoids, and gene silencing therapies.
Main Results:
- Current medications effectively lower intraocular pressure, forming the cornerstone of glaucoma and OH treatment.
- Novel agents are being developed to enhance aqueous humor outflow and address complex disease mechanisms.
- Improved drug delivery methods are crucial to overcome poor patient adherence.
Conclusions:
- Existing ocular hypotensive medications are effective but novel mechanisms and delivery systems hold promise for future glaucoma control.
- Continued research into new therapeutic targets and delivery methods is essential for more effective management of glaucoma and prevention of blindness.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
01:22Drug Delivery: Miscellaneous Routes
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.